Navigation Links
Clinical Update - Debio 9902 SR in Alzheimer's Disease

Successful DSMB Review From Ongoing Phase II BRAINz Study

LAUSANNE, Switzerland, March 4 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, announced today that following a meeting of the independent Data Safety Monitoring Board (DSMB), the Company received a recommendation to continue its Phase II BRAINz study with Debio 9902 SR (sustained release) for the treatment of Alzheimer's disease (AD),without modification.

The DSMB's objective is to monitor the well being and safety of patients participating in a study and to review the safety data throughout its duration.

"This recommendation by the DSMB authorising Debiopharm to continue the BRAINz study confirms the safety profile of Debio 9902 SR" said David Wilkinson, from MARC, Moorgreen Hospital, Southampton, England and Principal Investigator in the United Kingdom, who presented this recommendation at the 10th International Hong Kong Springfield Symposium on Advances in Alzheimer Therapy.

About Debio 9902 SR

Debio 9902 SR is a novel AChE inhibitor which is administered once every 4 weeks. It is transformed non-enzymatically into its active compound, huperzine A (hup A). Hup A has been used in China for centuries to treat distinct disorders such as memory loss, schizophrenia and hypertension, and is widely used in North America and Europe as a food additive to enhance cognition and neuroprotection. The dual mode of action of Debio 9902 SR as a N-methyl-D-aspartate receptor antagonist and an AChE inhibitor, positions it as a third generation anti-Alzheimer's product by improving the general condition and cognitive functions of affected patients as well as having the potential of being a neuroprotectant. In addition, Debio 9902 SR once a month formulation aims to increase the benefit of the treatment by offering a better safety profile compared to already marketed AChE inhibitors, by increasing the compliance and -thus- the overall benefit for both the patients and their relatives.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit:

Debiopharm S.A. Contacts

Herve Porchet

VP, Medical Affairs

Tel.: +41-21-321-01-11

Fax: +41-21-321-01-69

Emmanuel Tamches

Medical Director

Tel.: +41-21-321-01-11

Fax: +41-21-321-01-69

Additional Media Contacts

In London


Brian Hudspith

Tel: +44-20-7379-5151

In New York

Russo Partners, LLC

Wendy Lau

Tel: +1-212-845-4272

Fax: +1-212-845-4260

SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Winnick Family Clinical Research Center Celebrates 6th Anniversary
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
4. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
5. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
6. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
7. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
8. Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
9. Boston Scientific Announces Addition to Clinical Sciences Organization
10. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
11. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015 Researchers at the Broad ... for Brain Research at MIT have engineered changes to ... down on "off-target" editing errors. The refined technique addresses ... of genome editing. Science , Feng ... of the approximately 1,400 amino acids that make up ...
(Date:12/1/2015)... Dec. 01, 2015 ... of the "2016 Europe Cell Surface ... Technologies, Competitive Strategies, Opportunities for Suppliers--France, Germany, ... offering. --> ) has ... Europe Cell Surface Markers: Country Volume and ...
(Date:12/1/2015)... , Dec. 1, 2015  Symic, a clinical-stage ... the extracellular matrix (ECM), today announced that it has ... advance the company,s pipeline, including its lead candidates SB-030 ... and includes the participation by all existing major investors, ... brings the total capital raised by Symic to over ...
(Date:12/1/2015)... December 1, 2015 ... the  "2016 U.K. Virology and Bacteriology Testing ... 100 Tests, Supplier Shares by Test, Innovative ... their offering.  --> ) ... U.K. Virology and Bacteriology Testing Market: Sales ...
Breaking Biology Technology:
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
(Date:11/11/2015)... 11, 2015   MedNet Solutions , an innovative SaaS-based ... research, is pleased to announce that it will be a ... event, to be held November 17-19 in ... live demonstrations of iMedNet , MedNet,s easy-to-use, ... iMedNet has been able to deliver time and cost ...
Breaking Biology News(10 mins):